177Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.

CONCLUSION: A novel SST-analog, 177Lu-DOTA-EB-TATE, has the potential to be translated from bench to bedside for the targeted therapy of patients characterized by high uptake of SST- analogs in metastatic lesions.
PMID: 33355247 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 22, 2020 Category: Cancer & Oncology Authors: Thakur S, Daley B, Millo C, Cochran C, Jacobson O, Lu H, Wang Z, Kiesewetter DO, Chen X, Vasko VV, Klubo-Gwiezdzinska J Tags: Clin Cancer Res Source Type: research